Drug Clinical Trials List

Display 581 - 590 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries.	Bayer	Ongoing	Riociguat	4	18303	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh)
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD)	Bayer	Terminated	Finerenone	3	BAY 94-8862 17530	King Abdulaziz University Hospital (Jeddah)
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease	Bayer	Terminated	Finerenone	3	BAY 94-8862 16244	King Abdulaziz University Hospital (Jeddah)
"A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2"	Bayer	Terminated	BAY 80-6946/Copanlisib	3	BAY 80-6946 / 17322	King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam)
Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer	AstraZeneca	Ongoing	MEDI4736/Paclitaxel	2	ESR-14-10649	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)	AstraZeneca	Ongoing	MEDI4736+Tremelimumab	3	D419AC00003	King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam)
Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions.	SFDA	Completed	Lipitor® lovarst tablet	4	42370	saudi Ajal
RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors	Bayer	Ongoing	Nexavar (Sorafenib)	4	17852	King Faisal Specialist Hospital and Research Center (Riyadh)
Treatment Patterns, Outcomes, and Resource Use Study For Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-Squamous)in Kingdom of Saudi Arabia and United Arab Emirates	Bristol-Myers Squibb	Ongoing	-	4	CA209454	King Abdulaziz Medical City NG (Riyadh)
SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	Roche	Ongoing	N/A	4	ML29618	King Abdulaziz Medical City NG (Riyadh)